Likely Sales Slump Puts (Still More) Heat On Amgen’s Denosumab To Win
This article was originally published in The Pink Sheet Daily
Executive Summary
Analyst questions whether the bone drug’s efficacy can beat Zometa’s by the necessary 15 percent.
You may also be interested in...
Will Safety Issues Derail Denosumab? FDA Sets Advisory Cmte. Slot
Amgen’s much-ballyhooed monoclonal antibody, now called Prolia, faces safety questions at the Aug. 13 Advisory Committee for Reproductive Health Drugs meeting.
Will Safety Issues Derail Denosumab? FDA Sets Advisory Cmte. Slot
Amgen’s much-ballyhooed monoclonal antibody, now called Prolia, faces safety questions at the Aug. 13 Advisory Committee for Reproductive Health Drugs meeting.
After D-mab: Next-Generation Osteoporosis Drugs Focus On Building Bone
Anti-resorptive denosumab is what Amgen is counting on for its future growth. But denosumab may be the last of the current generation of drugs which prevent bone breakdown: newer drugs in development help build bone.